...the two have been investing roughly 70% of their overall venture funding in the sector. Casdin Capital... ...any series, and excludes venture debt. Source: BioCentury’s BCIQ database
Gunjan Ohri
OrbiMed Advisors
Arch Venture Partners
RA Capital Advisors
Casdin Capital
Surveyor...
...discount to Beam’s closing price Friday of $113.04. The syndicate included Perceptive Advisors, Farallon Capital, Casdin Capital... ...that could lead to protection from heart attack. Wellington Management led the round alongside co-leader Casdin Capital...
...in the series B were Surveyor Capital, Invus, Wellington Management Co., Nexttech Invest, OrbiMed Advisors, Casdin Capital... ...Epidermal growth factor receptor 2
BC Staff
CVnCoV
CT-0508 (CARMA-0508)
ARGX-113 (efgartigimod)
Bayer AG
CureVac N.V.
Boxer Capital
EcoR1 Capital
Omega Funds
Vida Ventures
Surveyor Capital
Invus
Wellington Management
OrbiMed
Casdin Capital
Woodline...
...the two have been investing roughly 70% of their overall venture funding in the sector. Casdin Capital... ...any series, and excludes venture debt. Source: BioCentury’s BCIQ database
Gunjan Ohri
OrbiMed Advisors
Arch Venture Partners
RA Capital Advisors
Casdin Capital
Surveyor...
...discount to Beam’s closing price Friday of $113.04. The syndicate included Perceptive Advisors, Farallon Capital, Casdin Capital... ...that could lead to protection from heart attack. Wellington Management led the round alongside co-leader Casdin Capital...
...in the series B were Surveyor Capital, Invus, Wellington Management Co., Nexttech Invest, OrbiMed Advisors, Casdin Capital... ...Epidermal growth factor receptor 2
BC Staff
CVnCoV
CT-0508 (CARMA-0508)
ARGX-113 (efgartigimod)
Bayer AG
CureVac N.V.
Boxer Capital
EcoR1 Capital
Omega Funds
Vida Ventures
Surveyor Capital
Invus
Wellington Management
OrbiMed
Casdin Capital
Woodline...